lorcaserin and Epilepsies--Myoclonic

lorcaserin has been researched along with Epilepsies--Myoclonic* in 3 studies

Reviews

1 review(s) available for lorcaserin and Epilepsies--Myoclonic

ArticleYear
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
    CNS drugs, 2022, Volume: 36, Issue:2

    Lorcaserin, a selective serotonin 5-HT

    Topics: Animals; Anticonvulsants; Benzazepines; Disease Models, Animal; Drug Development; Epilepsies, Myoclonic; Humans; Risk Assessment; Serotonin 5-HT2 Receptor Agonists

2022

Other Studies

2 other study(ies) available for lorcaserin and Epilepsies--Myoclonic

ArticleYear
A new school of drug discovery.
    Lab animal, 2017, 06-23, Volume: 46, Issue:7

    Topics: Animals; Anti-Obesity Agents; Anticonvulsants; Benzazepines; Benzimidazoles; Disease Models, Animal; Drug Discovery; Epilepsies, Myoclonic; High-Throughput Screening Assays; Humans; United States; United States Food and Drug Administration; Zebrafish

2017
Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome.
    Brain : a journal of neurology, 2017, 03-01, Volume: 140, Issue:3

    Dravet syndrome is a catastrophic childhood epilepsy with early-onset seizures, delayed language and motor development, sleep disturbances, anxiety-like behaviour, severe cognitive deficit and an increased risk of fatality. It is primarily caused by de novo mutations of the SCN1A gene encoding a neuronal voltage-activated sodium channel. Zebrafish with a mutation in the SCN1A homologue recapitulate spontaneous seizure activity and mimic the convulsive behavioural movements observed in Dravet syndrome. Here, we show that phenotypic screening of drug libraries in zebrafish scn1 mutants rapidly and successfully identifies new therapeutics. We demonstrate that clemizole binds to serotonin receptors and its antiepileptic activity can be mimicked by drugs acting on serotonin signalling pathways e.g. trazodone and lorcaserin. Coincident with these zebrafish findings, we treated five medically intractable Dravet syndrome patients with a clinically-approved serotonin receptor agonist (lorcaserin, Belviq®) and observed some promising results in terms of reductions in seizure frequency and/or severity. Our findings demonstrate a rapid path from preclinical discovery in zebrafish, through target identification, to potential clinical treatments for Dravet syndrome.

    Topics: Adolescent; Animals; Animals, Genetically Modified; Anticonvulsants; Benzazepines; Benzimidazoles; Child; Disease Models, Animal; Epilepsies, Myoclonic; Female; Gene Expression Regulation, Developmental; Humans; Larva; Male; NAV1.1 Voltage-Gated Sodium Channel; Protein Binding; Receptors, Serotonin; Seizures; Serotonin; Signal Transduction; Treatment Outcome; Zebrafish

2017